drugset / Trial / NCT02395978
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
Timeline
- Start
- 2015-04-10
- Primary completion
- 2019-03-12
- Completion
- 2019-03-18
Outcome
Missed primary endpoint
registry analysis (superiority test); Part II: 2 PDC-1421 Capsule vs Part II: 1 PDC-1421 Capsule Plus 1 Placebo vs Part II: 2 Placebo; p = 0.393; Kruskal-Wallis NCT02395978 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PDC-1421 | Unknown | 1 unknown | Oral |
| Subject | PDC-1421 | Unknown | 2 unknown | Oral |